Open
Do GLP-1 receptor agonists cause more adverse events & safety than other treatments?
Also asked versus placebo.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Doubtful. So far, the results disagree.
NoUnsureYes
- Belief
- 0.22 (range 0.00–0.55)
- Trials for
- 4
- Trials against
- 14
- Inconclusive
- 2
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 594
- With posted results
- 184
- Published papers
- 44
Of 200 decided analyses: 124 favor glp-1 receptor agonists, 66 find no difference, 10 favor the comparator.
Papers
- The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.Trial report · 2015
- Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: insights from an EXSCEL post-hoc analysis.Trial report · 2025
- Once-Weekly Exenatide in Youth With Type 2 Diabetes.Trial report · 2022
- Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial.Trial report · 2019
- Pharmacological and non-pharmacological strategies for obese women with subfertility.Meta-analysis / systematic review · 2021
- Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.Meta-analysis / systematic review · 2024
Trials
- A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and GlimepirideNCT01075282 · 31 posted results
- A Phase Ib, Multicenter, Placebo and Active- Comparator-Controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Subjects With Type 2 Diabetes MellitusNCT01982630 · 61 posted results
- A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on MetforminNCT00734474 · 38 posted results
- The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)NCT01126580 · 23 posted results
- Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 DiabetesNCT01923181 · 20 posted results
- A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)NCT01064687 · 38 posted results
- A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 DiabetesNCT02692716 · 7 posted results
- Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 DiabetesNCT02461589 · 4 posted results